Company Overview of Foresight Biotherapeutics, Inc.
Foresight Biotherapeutics, Inc. develops treatments and therapies to address unmet needs in ophthalmology and otolaryngology. Its products include FST-100 for the clinical needs of microbial eradication and reduction in inflammation associated with ocular infections, as well as for adenoviral conjunctivitis; and FST-201, a topical formulation of povidone-iodine and dexamethasone for the treatment of acute otitis media. The company was incorporated in 2008 and is based in New York, New York. As of July 30, 2015, Foresight Biotherapeutics, Inc. operates as a subsidiary of Shire plc.
50 West 57th Street
New York, NY 10019
Founded in 2008
Key Executives for Foresight Biotherapeutics, Inc.
Similar Private Companies By Industry
|Enturia, Inc.||United States|
|CanX, Inc.||United States|
|Medican Systems Inc.||United States|
|Shire US, Inc.||United States|
|Hypnion, Inc.||United States|
Recent Private Companies Transactions
August 3, 2015
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Foresight Biotherapeutics, Inc., please visit www.foresightbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.